

TRUST BOARD
30th July 2015

TITLE	Monitor Q1 2015/16 submission
EXECUTIVE SUMMARY	<p>In accordance with Monitor's <i>Risk Assessment Framework 2014/15</i>, the Trust is required to make a quarterly submission to Monitor on the Trust's performance in both financial, quality and operational terms. This includes performance against various national targets and indicators.</p> <p>At the start of the new year the Trust also submits an Annual Plan with an accompanying declaration of risks against targets and indicators.</p>
BOARD ASSURANCE (RISK)/ IMPLICATIONS	The Finance Committee scrutinises the financial reports on a monthly basis with minutes of the meeting presented in the open Board meeting. The operational performance report is presented in the open Board meetings and regularly scrutinised.
LINK TO STRATEGIC OBJECTIVE	The Monitor submission links to all Trust Strategic Objectives.
STAKEHOLDER/ PATIENT IMPACT AND VIEWS	None taken.
EQUALITY AND DIVERSITY ISSUES	None known.
LEGAL ISSUES	Insufficient or inaccurate declaration of future risk to Monitor can impact the Trust's regulatory ratings and potentially our Licence.
The Trust Board is asked to:	<p>The Board is asked to review and agree the content of the Q1 submission as:</p> <ul style="list-style-type: none"> ▪ Governance Declaration: 2 ▪ Finance Declaration: 2
Submitted by:	Lorraine Knight, Interim Chief Operating Officer Simon Marshall, Director of Finance & Information
Date:	23 rd July 2015

Decision: For Approval

Monitor Q1 2015/16 submission**1 Introduction**

The Trust is required to submit the Quarter 1 Compliance Return to Monitor by 31st July. The Q1 return requires the Trust to declare risks against the governance and continuity of services rating. This paper details recommendations of risks to be made to Monitor as at Q1.

2 Governance declaration**Background**

The Governance declaration relates to the performance against national targets and indicators with the Board needing to certify that it:

"is satisfied that plans in place are sufficient to ensure on-going compliance with all existing targets (after the application of thresholds) as set out in Appendix A of the Risk Assessment Framework; and a commitment to comply with all known targets going forwards"

3 Performance against national targets and indicators

In Q1 2015/16 the Trust has not achieved the:

- A&E four hour standard (93.03%); and
- Admitted Referral to Treatment Time (RTT) target - following failure of the target in April (88.55%)*.

*Under the *Risk Assessment Framework* (RAF) failure of any month in the quarter leads to failure of the entire quarter for RTT.

This is an improvement on Q4 2014/15 with the Trust previously not achieving the:

- A&E four hour standard (92.06%);
- Admitted Referral to Treatment Time (RTT) target - following failure of the target in all three months – (88.9%);
- Cancer 62 day Urgent GP referral for suspected cancer (77.5%);
- Cancer 31 day wait for second or subsequent treatment (86.8%); and
- Cancer 2 week (all cancers) (91%).

In the operating plan submitted to Monitor in April the Trust declared risk against the A&E

waiting time target; RTT – admitted and non-admitted; and 62 day, 31 day and 2 week Cancer targets.

4 Governance Risk Rating

The Trust's Governance rating is currently 'under review'. Monitor's website notes that this is due to:

“Monitor requesting further information following multiple breaches of the A&E, Cancer and referral to treatment (admitted) targets and a deterioration in the forecast financial position, before deciding next steps”.

Monitor are likely to undertake their Q1 review (through to the end of August) before deciding whether to take any further steps which could include investigating the Trust.

5 Recommended declarations

5.1 A&E waiting time target.

The Trust did not achieve the waiting time target (95%) in quarter 1 2015/16 with performance of 93.03%. The Trust failed each month in the quarter with performance of:

- June: 93.08%
- May: 94.26%
- April: 92.56%

Detail on performance against this standard and the actions to resolve is included within the Performance Report elsewhere on the agenda.

Due to the continuing pressures on A&E **it is recommended that the Trust declare a risk of failing to achieve the waiting time target in Q2 2015/16.**

5.2 Referral to Treatment Time target (admitted)

The Trust did not meet the 18 weeks standards for the admitted target (90%) in Q1 due to failure of the target in April 2015 (*failure of any month in the quarter leads to failure of the quarter*). Performance for the three months was:

- June: 92.21%
- May: 92.55%
- April: 88.55%

Further detail on the performance against the RTT target is included in the Performance Report elsewhere on the agenda.

Due to sustained improvement of this target in May and June continuing into July **it is not recommended to declare a risk of failure of this target in Q2 2015/16.**

Referral to Treatment Time target (non-admitted)

5.3

The Trust declared a risk against achievement of the non-admitted RTT target (95%) in the Annual Plan for 2015/16. This was due to concerns in relation to endoscopy.

The Trust commenced its programme of additional endoscopy activity during June and is now beginning to see a reduction in overdue endoscopy procedures in line with backlog reduction plans. Prospective endoscopy capacity now matches anticipated demand, inclusive of the required capacity to reduce the existing backlog over the next 10-12 weeks.

Non-admitted performance for Q1 was:

- June: 95.94%
- May: 96.29%
- April: 95.01%

The Trust has been compliant with the non-admitted target throughout Q1 and as such it is **recommended that a risk is not declared.**

Referral to Treatment Time - Incomplete target

5.4

The Trust continues to meet this target (92%) with strong performance against the target in Q1:

- June: 96.26%
- May: 96.73%
- April: 96.15%

The Trust has been compliant with the incomplete target throughout Q1 and as such it is **recommended that a risk is not declared.**

62 Day Cancer

5.5

The Trust reported compliance for the '62 day wait for first treatment - Urgent GP referral for suspected cancer' standard (85%) in Q1 with performance of 87.6%.

Although this target was achieved in Q1 preliminary July numbers are highlighting that this target may be breached in the month which could lead to failure of the quarter. Although detailed analysis has not been conducted at this point a complex case mix of patients presenting for treatment and reduced staff availability may have led to this failure in July. The Trust needs to review all speciality pathways and trigger points for escalation to ensure that prospective difficulties in achieving this target are flagged earlier in future. Along with all applicable Trusts Monitor have asked ASPH to write to them by the end of August detailing a gap analysis and recovery plan for achievement of the 62 day standard.

Despite compliance with this target in Q1 the Trust has experienced difficulties in July and hence it is **recommended that a risk is declared against this target for Q2 15/16.**

31 day and two week cancer

- 5.6 The Trust achieved both the 31 day (surgery target - 94%; Anti-cancer drug target – 98%) and two week cancer targets (both 93%) in Q1 with performance of 100% (31 day) and 93.9% (2 week urgent referrals) and 94.7% (2 week symptomatic breast patients). The Trust forecast continued achievement in Q2 15/16 and as such it is **recommended no declaration of risk is made against these targets.**

C-Difficile

- 5.7 The Trust has had 18 cases of C-Difficile in 2014/15 with a threshold of 17 set for 2015/16. At the end of June the Trust has had 4 cases with none in June. As such it is recommended that **no risk is declared to breaching the target in 2015/16.**

6 Finance Declaration

The Finance Committee reviewed the financial aspects of the Monitor Compliance Return for Quarter 1 2015/16 at its meeting held on 23rd July 2015.

The submission to Monitor comprises the Statement of Comprehensive Income, Statement of Financial position and Cashflow Statement as at 30th June 2015. These drive the Continuity of Service Risk Rating for the quarter (year to date). At 30th June 2015 the Trust has a Continuity of Service Risk Rating of '3' this is against a plan of '2'.

Monitor measures the Trust against a capital expenditure reforecast trigger. Essentially if the Trust has spent less than 85% or more than 115% of its plan to date then the Trust Board must approve a reforecast capital profile and make a Board declaration. The Trust was within the set tolerances for this measure at quarter 1 with 90% of plan spent.

Recommended declaration

The Finance Declaration that the Trust are asked to make is:

"the Board anticipates that the Trust will continue to maintain a Continuity of Service risk rating of at least 3 over the next 12 months".

The Finance Committee discussed the recommendation that should be made in relation to the maintenance of the 'continuity of service' risk rating of at least '3' over the next 12 months and agreed that at this point it was not possible to confirm a '3' for the next 12 months due to the forecast Q2 position (which had already been flagged to Monitor at Q4 14/15) and the uncertainty of the Q1 position next year without a budget in place.

7 Recommendation

The Board is asked to review and approve a Finance and Governance Declaration of '2' ('not confirmed').

As part of this Governance declaration risks are being declared against the:

- A&E waiting time target; and

- 62 day wait for first treatment (Urgent GP referral for suspected cancer)